Sean‘s pick this week is spider_plot by Moses. Last week, we looked at the custom chart I created.  This week, we’ll look at authoring it. Contents Authoring the Custom Chart Full... read more >>

Alex Wolff in Human Capital.; Credit: Vertical Entertainment/Human Capital (2019)

Larry Mantle and KPCC film critics Lael Loewenstein, Claudia Puig and Tim Cogshell review this weekend’s new (streaming and VOD) movie releases.

• "Human Capital" on DirecTV

• "Crip Camp" on Netflix

• "The Platform" on Netflix

• "Blow The Man Down" on Amazon Prime Video

• "Phoenix, Oregon" on film's website

• "The Dog Doc" on Amazon Prime Video

• "Hooking Up" on Xfinity OnDemand

​CORRECTION: The film Human Capital is available on all on-demand platforms as of March 20th.

Guests:

Claudia Puig, film critic for KPCC and president of the Los Angeles Film Critics Association (LAFCA); she tweets @ClaudiaPuig

Lael Loewenstein, KPCC film critic and film columnist for the Santa Monica Daily Press; she tweets @LAELLO

Tim Cogshell, film critic for KPCC, Alt-Film Guide and CineGods.com; he tweets @CinemaInMind

This content is from Southern California Public Radio. View the original story at SCPR.org.

Director Eliza Hittman on the set of her film "Never Rarely Sometimes Always".
; Credit: Focus Features/Never Rarely Sometimes Always (2020)

The film “Never Rarely Sometimes Always” was slated for a theatrical release in March, but due to COVID-19 screenings were postponed. Instead, the film is out on digital this week, currently sporting a 98 percent rating on Rotten Tomatoes and receiving critical acclaim both here on FilmWeek and nationwide as one of the best films of 2020 so far.

Writer-director Eliza Hittman’s third feature-length film is about two teenage girls Skylar (Talia Ryder) and Autumn (Sidney Flanagan) from rural Pennsylvania who travel to New York City for medical help after an unplanned pregnancy. Hittman says the idea for the film came to her when she read in a book about how some women in Ireland, which up until recently had very strict laws against abortions, would travel from Ireland to London in 24 hours just to get a procedure. It struck her as worthy of a screenplay, and the idea was born. As part of her research for the film Hittman went to a small coal-mining community in rural Pennsylvania and, even though she wasn’t pregnant, visited pregnancy centers, got tested, and talked with women getting treatment and counseling so she could, as she says, “write the scenes with credibility.”

Today on FilmWeek, we’ll air “The Frame” host John Horn’s interview with “Never Rarely Sometimes Always” director Eliza Hittman where the two discuss how Hittman came up with the idea for the film, her journey to rural America to find out what visiting pregnancy centers there is like, and how that informed the way she conceived and wrote the film.

Guest:

Eliza Hittman, writer and director of “Never Rarely Sometimes Always”

This content is from Southern California Public Radio. View the original story at SCPR.org.

New research has shed light on the factors needed to successfully implement pilot projects designed to reduce the dumping of unwanted fish by fishermen. The analysis of 15 European projects highlights the importance of involving the fishing industry in developing and implementing pilot projects.

'California Mountain Lions,' Episode 7: Human Interaction

4 awesome discoveries you probably didn't hear about this week -- Episode 31

NSF Science Now: Episode 65

4 awesome discoveries you probably didn't hear about this week -- Episode 32

World War II veterans Pyotr Vorobyev (left), 90, and Pavel Yeroshenko, 94, attend a performance in Minsk by the 120th Rogachev Guards Mechanized Brigade of the Belarusian Armed Forces ahead of the 75th anniversary of the victory in World War II. Belarus is raising eyebrows — and concerns — by going ahead with a mass military parade marking the anniversary on Saturday.; Credit: Natalia Fedosenko/TASS

With the coronavirus forcing much of Europe to tone down public celebrations this week marking the 75th anniversary of the end of World War II, the small nation of Belarus is raising eyebrows — and concerns — by going ahead with a mass military parade in the capital Minsk on Saturday.

The move reflects the business-as-usual approach of the country's longtime president, Alexander Lukashenko — a former Soviet collective farm director leading what the U.S. once dubbed the last dictatorship in Europe.

As the coronavirus has raced across the globe, Lukashenko has dismissed the pandemic as mass "psychosis" — a disease easily cured with a bit of vodka, a hot sauna or time spent playing hockey or doing farm work on one of country's legendary Soviet-designed tractors.

The country's soccer league still competes. Belarus' schools opened after a short delay. And annual Victory Day celebrations will go on.

The government "simply cannot cancel the parade," the Belarusian leader said in a Cabinet meeting this week. "It's an emotional, deeply ideological event."

In a rare concession to at least some social distancing measures, Lukashenko has urged Belarusian men to spend time with their families, rather than their mistresses. But behind the theatrics sits a wily politician who plays to his base in the country's towns and villages, analysts say.

"Lukashenko prioritizes combating panic rather than combating the pandemic," Artyom Shraibman, a Minsk-based political analyst with Sense Analytics, tells NPR. "He downplays the threat, and of course he's very concerned about [the] state of [the] economy."

Shraibman notes similar echoes coming out of the Trump White House.

Belarus has reported over 21,000 suspected coronavirus cases and more than 120 deaths — comparatively low in the global count, but one of the fastest-growing infection rates in Europe, the World Health Organization says.

Amid the growing crisis, Belarusian civil society is rallying to fix what Lukashenko will not. With many Belarusians now self-isolating by choice, even the country's health ministry has endorsed some public distancing measures over Lukashenko's advice.

Volunteers have raised money to buy personal protective gear for hospitals. Restaurants have donated food. Hotels provide rooms pro bono to medical workers. Private businesses have raised funds.

"People who normally don't talk to each other are working together to help," says Andrej Stryzhak of #ByCovid19, a group of volunteer activists leading crowdfunded efforts to equip health workers across the country. "It's been magical and I don't use that word lightly."

Stryzhak says many are bracing for the aftershocks of Saturday's Victory parade, where attendance isn't required but there are reports of pay bonuses given to those who show up.

"We believe in statistics. And the experts and doctors tell us that if there's a crowd, then expect a new spike in cases a week or two later," says Stryzhak. "Belarus isn't Mars," he adds, noting that the country is as susceptible to the virus as any other.

Meanwhile, Lukashenko's contrarian approach has also fueled a rift with Belarus' big brother to the east. Russia has embraced lockdowns amid its own soaring coronavirus infection rates.

This week, the Belarusian leader ordered the expulsion of a journalist from Russia's Channel 1 state television network after it aired a report criticizing Lukashenko for risking lives and ignoring the pandemic.

"Leave us alone and don't count your chickens before they hatch," said Lukashenko. "Later we'll sit and find out who was right."

This content is from Southern California Public Radio. View the original story at SCPR.org.

Birth control pills in 1976 in New York. The birth control pill was approved by the FDA 60 years ago this week.; Credit: /Bettmann/Getty Images

Updated at 9:44 a.m. ET

As a young woman growing up in a poor farming community in Virginia in the 1940 and '50s, with little information about sex or contraception, sexuality was a frightening thing for Carole Cato and her female friends.

"We lived in constant fear, I mean all of us," she said. "It was like a tightrope. always wondering, is this going to be the time [I get pregnant]?"

Cato, 78, now lives in Columbia, S.C. She grew up in the years before the birth control pill was approved by the U.S. Food and Drug Administration, on May 9, 1960. She said teenage girls in her community were told very little about how their bodies worked.

"I was very fortunate; I did not get pregnant, but a lot of my friends did. And of course, they just got married and went into their little farmhouses," she said. "But I just felt I just had to get out."

At 23, Cato married a widower who already had seven children. They decided seven was enough.

By that time, Cato said, the pill allowed the couple to avoid having more babies — and she eventually was able to go on to college.

"It was just like going from night to day, as far as the freedom of it," Cato said. "And to know that I had control, that I had choice, that I controlled my body. It gave me a whole new lease on life."

Loretta Ross, an activist and visiting women's studies professor at Smith College, was among the first generation of young women to have access to the birth control pill throughout their reproductive years.

Ross, now 66, said by the time she came of age around 1970, the pill was giving young women more control over their fertility than previous generations had enjoyed.

"We could talk about having sex – not without consequences, because there were still STDS ... but at the same time, with more freedom than our foremothers had," Ross said. "So it changed the world."

For all it's done for women, Ross said that the pill has a complex and controversial history; it was first tested on low-income women in Puerto Rico. Ross said the pill also has limitations; she'd like to see it made available over the counter, as it is in some countries – not to mention, a pill for men.

When the pill was approved in 1960, women had few relatively few contraceptive options, and the pill offered more reliability and convenience than methods like condoms or diaphragms, said Dr. Eve Espey, chair of the Department of Ob/Gyn and Family Planning at the University of New Mexico.

"There was a huge, pent-up desire for a truly effective form of contraception, which had been lacking up to that point," Espey said.

By 1965, she said, 40% of young married women were on the pill.

For Pat Fishback, now 80 and living in Richmond, Va., the newly-available pill allowed her to delay having children in her early 20s until she'd been married for a couple of years.

"It also made having children a positive experience," Fishback said. "Because we had actually, emotionally and intellectually, gotten to the point where we really desired to have children."

It took a bit longer for unmarried women to gain widespread access to the pill and other forms of contraception: Linda Gordon, 80, a historian at New York University, remembers the stigma around single women and contraception at the time.

"When I was in college, a number of women had a wedding ring – a gold ring –that we would pass around and use when we wanted to go see a doctor to get fitted for a diaphragm," Gordon said. "In other words, there were people finding their way to do that, even then."

The pill also gave rise to a variety of other forms of hormonal contraception, many of which are popular today, Gordon said. According to the Centers for Disease Control and Prevention, nearly 13% of American women of reproductive age use the pill — making it the second most popular form of contraception, after female sterilization.

Gordon said that 60 years after the pill's approval, contraception remains a contentious political issue.

Just this week, the U.S. Supreme Court heard arguments in a case involving the birth control mandate in the Affordable Care Act. A decision on whether some institutions with religious or moral objections can deny contraceptive coverage to their employees is expected in the months to come.

This content is from Southern California Public Radio. View the original story at SCPR.org.

Maurice Jackson of Proven and Probable speaks with Andy Schectman, president of Miles Franklin Precious Metals Investments, about the present situation with physical precious metals.

NSF Science Now: Episode 65

4 awesome discoveries you probably didn't hear about this week -- Episode 32

Source: Streetwise Reports   04/28/2020

News Flash: On May 7, CloudMD announced that it is partnering with IDYA4 Corp. for it to resell the health technology firm's Livecare technology in the U.S.. Read more here.

News Flash: On May 4, CloudMD announced that it is partnering with Save-On-Foods grocery stores and Pure Integrative Pharmacy to pilot on demand, integrated virtual patient care through telemedicine kiosks placed in pharmacies' existing consult rooms. Read more here.

As people are avoiding going to doctor's offices and hospitals during the coronavirus pandemic, telemedicine has taken off. Two investment professionals, Bruce Campbell and Keith Schaefer, have called CloudMD Software & Services Inc. (DOC:CSE; DOCRF:OTCQB; 6PH:FSE), a small-cap Canadian telemedicine firm, a top pick.

Bruce Campbell, founder and portfolio manager of Stonecastle Investment Management, spoke about CloudMD on April 27 on BNN:

"The first top pick is CloudMD Software, a technological medical play. We've tried to look at opportunities that are really going to be able to take advantage of Covid and this is one of the ones that we think is; what they do is telemedicine.

"The jumping off point for TeleHealth is here and I think CloudMD is the best pure-play TeleHealth stock right now." - Keith Schaefer

If you look back at a year ago, where everyone had to go to the doctor, and now all of the different provinces have opened up billing codes, so that now we don't have to go into a doctor's office. We can do a virtual doctor's visit and the doctor gets paid just like they do with an in-house appointment. Obviously with everything that has happened with this crisis, people really don't want to go into a doctor's office and they need a prescription renewal or something like that.

If you look at CloudMD's peers in the U.S., there is a company called Teladoc, which is a big U.S. company that does the same thing. Obviously, the size of the market is different, but the multiple it trades at is multiple times higher than where CloudMD is.

CloudMD is just starting to gain adoption. They started off here in BC, they have moved to Ontario, and they are going to be rolling out really across the country, so tons of opportunity for a company like this. They will probably change the way that we view our doctor and our healthcare visits going forward."

Keith Schaefer, editor and publisher of Oil & Gas Investments Bulletin, is also following CloudMD, and wrote:

"An entirely new—and highly profitable—industry is being borne out in 2020—TeleHealth. CloudMD Software & Services Inc. (DOC:CSE; DOCRF:OTCQB; 6PH:FSE) is my favorite way to play TeleHealth. It's growing quickly with over 100,000 patients registered on its app and over 3000 doctors in 8 provinces in its Electronic Medical Records—EMR—system. It has MULTIPLE revenue streams and it just moved into Canada's largest market—Ontario—setting up an even faster growth rate.

The recent spread of coronavirus is only accelerating this. Covid-19 has forever changed how we all will think about visiting a hospital or seeing our doctor. We really don't want to do that at all, if possible. It will have a very positive and long lasting impact on TeleHealth.

TeleHealth companies in Canada are getting paid more money for services than bricks-and-mortar clinics, and have a fraction of the costs. Doctors want more of it, patients want more of it, government wants more of it—and the Market REALLY wants more of it. Everybody wins here; there is no downside.

The rapid scale-up and profitability is key for investors.

CloudMD is established, growing quickly and trading at a fraction of its peers. The average multiple of competitors in the sector trade at 5-7x revenue, and CloudMD is trading way below that at 2.5x per revenue. But realize that the Canadian use of telemedicine is still just a fraction of where it is in the U.S—so the quick, early upside is even bigger.

The market desperately wants to own TeleHealth right now. I see CloudMD as the best way to do that in the junior sector (where the leverage is!).

For this stock to have a major run all that needs to happen is for institutional investors to wake-up to the fact that the company exists. That's happening now with the company entering the province of Ontario—which has 14.5 million people—over one-third of Canada's population.

CloudMD is a fully integrated health care company—kind of like a hospital-in-the-sky. They do have five bricks-and-mortar clinics, but they also own their own EMR—Electronic Medical Records—system that operates in eight provinces and is used by over 3,000 doctors and is supported by an in-house 25 person development team. They have their own CloudMD app—which has over 100,000 registered patients already.

The EMR gives CloudMD a recurring monthly revenue stream, which The Street loves. The app gives them high-margin fees from doctors, specialists and groups like massage therapists & counselors. These people are revenue, not costs. As I said, full hospital-in-the-sky. Multiple revenue sources with lower costs.

To schedule a virtual doctor's appointment all that a patient has to do is download the free CloudMD app and then arrange an appointment with one of the doctors. There is zero charge for the patient and they can see a doctor very quickly.

CloudMD can scale up the number of patients VERY quickly—and they are. Every aspect of healthcare that's very fractured and disjointed will now be in the one CloudMD ecosystem.
Everyone wins with this system. Patients, doctors, the medical system, society, even investors. Everyone.

Doctors who have signed up with CloudMD work remotely from home or wherever they are (like their winter home down south). The rapid scale-up potential excites me. CloudMD can add in unlimited number of doctors and patients—so it has a virtually unlimited ability to scale quickly with little incremental cost.

Profit margins are wide and there is no cap on the number of customers that can be handled.

After a patient has an appointment, CloudMD bills the government directly just like every bricks-and-mortar clinic in Canada does. CloudMD records 100% of the revenue and gets to keep 30% of the billing for every patient that is seen through telemedicine, which is actually 10% more than what a bricks-and-mortar clinic receives. That is because the governments are trying to push TeleHealth. The doctor gets the other 70% and doesn't have to deal with any headaches of commuting or running a business.

Without the overhead of a bricks-and-mortar clinic, AND more revenue, CloudMD will be much more profitable than traditional healthcare stocks. Faster scale, more cash flow. And they just entered Canada's largest market. This is the right stock in the right market at the right time. That's the great thing about this business model. It's very scalable, very easy, and it grows very quickly.

CloudMD has been growing its recurring SAAS (Software-as-a-Service) revenue by 30% YoY with its EMR system. But this year the company is expecting that doctor growth to be much much higher—with a new full time sales team and the coronavirus pandemic. SaaS revenue is highly lucrative!

The jumping off point for TeleHealth is here and I think CloudMD is the best pure-play TeleHealth stock right now."

Read Keith Schaefer's entire article here.

Watch Bruce Campbell of StoneCastle Investments share his top picks: CloudMD, Lightspeed and Viemed.

Disclosure:
1) Keith Schaefer: I, or members of my immediate household or family, own shares of the following companies mentioned in this article: CloudMD. I personally am, or members of my immediate household or family are, paid by the following companies mentioned in this article: CloudMD. My company has a financial relationship with the following companies mentioned in this article: None. Additional disclosures are listed below.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees. As of the date of this article, an affiliate of Streetwise Reports has a consulting relationship with CloudMD. Please click here for more information. An affiliate of Streetwise Reports is conducting a digital media marketing campaign for this article on behalf of CloudMD. Please click here for more information.
3) Statements and opinions expressed are the opinions of the author and not of Streetwise Reports or its officers. The author is wholly responsible for the validity of the statements. The author was not paid by Streetwise Reports for this article. Streetwise Reports was not paid by the author to publish or syndicate this article. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security. Streetwise Reports requires contributing authors to disclose any shareholdings in, or economic relationships with, companies that they write about. Streetwise Reports relies upon the authors to accurately provide this information and Streetwise Reports has no means of verifying its accuracy.
4) This article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases. As of the date of this article, officers and/or employees of Streetwise Reports LLC (including members of their household) own securities of CloudMD, a company mentioned in this article.

Additional Disclosures